teleo-codex/agents/vida/musings/research-2026-04-12.md

type	domain	session	date	status
musing	health	22	2026-04-12	active

Research Session 22 — GLP-1 + Vulnerable Populations: Is the Compounding Failure Being Offset?

Research Question

Is there a direct study of micronutrient outcomes in food-insecure GLP-1 users, and are state or federal programs compensating for SNAP cuts to Medicaid GLP-1 beneficiaries — or is the "compounding failure" thesis from Sessions 20–21 confirmed with no offsetting mechanisms?

Why this question now: Session 21 found that GLP-1 users require continuous delivery infrastructure, that 22% develop nutritional deficiencies within 12 months, that 92% receive no dietitian visit, and that the OMA/ASN/ACLM/Obesity Society joint advisory explicitly recommends SNAP enrollment support as part of GLP-1 therapy — issued during OBBBA's $186B SNAP cuts. The double-jeopardy inference was structurally confirmed but not directly studied. Session 21 flagged this as a research gap.

Note: Tweet file was empty this session — no curated sources. All research is from original web searches.

Belief Targeted for Disconfirmation

Belief 1: Healthspan is civilization's binding constraint, and we are systematically failing at it in ways that compound.

Disconfirmation Target

Specific falsification criterion for the compounding failure thesis: If state-level Medicaid GLP-1 coverage is being maintained or expanded to offset federal SNAP cuts, or if food banks / community health organizations are systematically providing micronutrient supplementation for GLP-1 users, the "systematic dismantling of access infrastructure" claim weakens. The failure would be real but compensated — which is a fundamentally different structural picture than "compounding unaddressed."

Additionally: if a direct study of food-insecure GLP-1 users shows micronutrient deficiency rates similar to the general GLP-1 population (not elevated), the double-jeopardy inference may be overstated.

What I expect to find: State-level coverage is inconsistent and fragile — likely to find some states expanding while others cut. Food banks and CHWs are not systematically providing GLP-1 nutritional monitoring. The direct study doesn't exist. The compounding failure thesis will hold.

What would genuinely disconfirm: A coordinated federal or multi-state initiative that is actively offsetting SNAP cuts with targeted food assistance for Medicaid GLP-1 users, at scale. I expect NOT to find this.

Secondary Thread: Never-Skilling Detection Programs

Also targeting Belief 5: Clinical AI creates novel safety risks (de-skilling, automation bias)

Disconfirmation target: If medical schools are now implementing systematic pre-AI competency baseline assessments and "AI-off drill" protocols at scale, the "structurally invisible" and "detection-resistant" characterization of never-skilling weakens. The risk is real but being addressed.

What I Searched For

Primary thread:

• Direct studies of micronutrient deficiency in Medicaid/food-insecure GLP-1 users (2025-2026)
• State-level Medicaid GLP-1 coverage policies post-OBBBA
• Federal or state programs addressing GLP-1 nutritional monitoring for low-income patients
• SNAP + GLP-1 policy intersection: any coordinated response to double-jeopardy risk
• GLP-1 adherence in Medicaid vs. commercial insurance populations

Secondary thread:

• Medical school AI competency baseline assessment programs 2025-2026
• "Never-skilling" detection protocols in clinical training
• Health system "AI-off drill" implementation data
• Clinical AI safety mitigation programs at scale

Key Findings

1. DISCONFIRMATION TEST RESULT: Compounding failure thesis CONFIRMED — no operational offset

The disconfirmation question: Are state or federal programs compensating for SNAP cuts and state Medicaid GLP-1 coverage retreats?

Answer: No — the net direction in 2026 is more access lost, not less.

State coverage retreat (documented):

• 16 states covered GLP-1 obesity treatment in Medicaid in 2025 → 13 states in January 2026 (net -3 in 12 months)
• 4 states eliminated coverage effective January 1, 2026: California, New Hampshire, Pennsylvania, South Carolina
• Michigan: restricted to BMI ≥40 with strict prior authorization (vs. FDA-approved ≥30 threshold)
• Primary reason across all ideologically diverse states: COST — this is a structural fiscal problem, not ideological

The BALANCE model is NOT an offsetting mechanism in 2026:

• Voluntary for states, manufacturers, and Part D plans — no entity required to join
• Medicaid launch: rolling May–December 2026; Medicare Part D: January 2027
• No participating state list published as of April 2026
• States that cut coverage would need to voluntarily opt back in — not automatic
• Medicare Bridge (July–December 2026): explicitly excludes Low-Income Subsidy beneficiaries from cost-sharing protections — $50/month copay for the poorest Medicare patients

USPSTF pathway (potential future offset, uncertain):

• USPSTF has a B recommendation for intensive behavioral therapy for weight loss, NOT GLP-1 medications
• Draft recommendation developing for weight-loss interventions (could include pharmacotherapy)
• If finalized with A/B rating: would mandate coverage under ACA without cost sharing
• This is a future mechanism in development — no timeline, not yet operational

California cut is the most revealing datum: California is the most health-access-progressive state. If California is cutting GLP-1 obesity coverage, this is a structural cost-sustainability problem that ideological commitment cannot overcome.

2. Adherence Problem: Even With Coverage, Most Patients Don't Achieve Durable Benefit

The compounding failure is deeper than coverage:

• Commercially insured patients (BEST coverage): 36% (Wegovy) to 47% (Ozempic) adhering at 1 year
• Two-year adherence: only 14.3% still on therapy (April 2025 data presentation, n=16M+)
• GLP-1 benefits revert within 1-2 years of cessation (established in Sessions 20-21)
• Therefore: 85.7% of commercially insured GLP-1 users are not achieving durable metabolic benefit

Lower-income groups show HIGHER discontinuation rates than commercial average. Medicaid prior authorization: 70% of Medicaid PA policies more restrictive than FDA criteria.

The arithmetic of the full gap: (GLP-1 continuous delivery required for effect) × (14.3% two-year adherence even in commercial coverage) × (Medicaid PA more restrictive than FDA) × (state coverage cuts) × (SNAP cuts reducing nutritional foundation) = compounding failure at every layer

Complicating factor: low adherence in the best-coverage population means the problem isn't ONLY financial. Behavioral/pharmacological adherence challenges (GI side effects, injection fatigue, cost burden even with coverage) compound the access problem.

3. Micronutrient Deficiency: Now Systematic Evidence (n=480,825), Near-Universal Vitamin D Failure

Urbina 2026 narrative review (6 studies, n=480,825):

• Iron: 64% consuming below EAR; 26-30% lower ferritin vs. SGLT2 comparators
• Calcium: 72% consuming below RDA
• Protein: 58% not meeting targets (1.2-1.6 g/kg/day)
• Vitamin D: only 1.4% meeting DRI — 98.6% are NOT meeting dietary vitamin D needs
• Authors: "common consequence, not rare adverse effect"

The 92% dietitian gap remains unchanged. Multi-society advisory exists; protocol adoption lags at scale.

No direct study of food-insecure GLP-1 users found — research gap confirmed. The double-jeopardy (GLP-1 micronutrient deficit + food insecurity baseline deficit + SNAP cuts) remains structural inference, not direct measurement.

4. HFpEF + GLP-1: Genuine Divergence Between Meta-Analysis (27% Benefit) and ACC Caution

Meta-analysis (6 studies, 5 RCTs + 1 cohort, n=4,043): 27% reduction in all-cause mortality + HF hospitalization (HR 0.73; CI 0.60–0.90) Real-world claims data (national, 2018–2024): 42–58% risk reduction for semaglutide/tirzepatide vs. sitagliptin ACC characterization: "Insufficient evidence to confidently conclude mortality/hospitalization benefit"

This is a genuine divergence in the KB — two defensible interpretations of the same evidence body:

• ACC: secondary endpoints across underpowered trials shouldn't be pooled for confident conclusions
• Meta-analysis: pooling secondary endpoints = sufficient to show statistically significant benefit

What would resolve it: a dedicated HFpEF outcomes RCT powered for mortality/hospitalization as PRIMARY endpoint.

5. Never-Skilling / Clinical AI: Mainstream Acknowledgment Without Solution at Scale

The Lancet editorial "Preserving clinical skills in the age of AI assistance" (2025) confirms:

• Deskilling is documented (colonoscopy ADR: 28% → 22% after 3 months of AI use)
• Three-pathway taxonomy (deskilling, mis-skilling, never-skilling) now in mainstream medicine
• No health system is running systematic "AI-off drills" or pre-AI baseline competency assessments at scale
• JMIR 2026 pre-post intervention study: "informed AI use" training improved clinical decision-making scores 56.9% → 77.6% — but this is an intervention study, not scale deployment

The never-skilling detection problem remains unsolved: you cannot lose what you never had, and no institution is measuring pre-AI baseline competency prospectively before AI exposure.

Follow-up Directions

Active Threads (continue next session)

• Continuous-treatment model claim: READY TO EXTRACT. Three independent confirming sources now available (GLP-1 rebound from Session 20, food-as-medicine reversion from Session 17, antidepressant relapse from Session 21). The pharmacological/dietary (continuous delivery required) vs. behavioral/cognitive (skill-based partial durability) distinction is fully documented. Target file: domains/health/pharmacological-dietary-interventions-require-continuous-delivery-behavioral-cognitive-provide-skill-based-durability.md

• GLP-1 HFpEF divergence file: READY TO WRITE. Session 21 identified it, this session confirmed the evidence. Create domains/health/divergence-glp1-hfpef-mortality-benefit-vs-guideline-caution.md. Links: meta-analysis (27% benefit), ACC statement (insufficient evidence), sarcopenic obesity paradox archive, weight-independent cardiac mechanism. "What would resolve this" = dedicated HFpEF outcomes RCT with mortality as primary endpoint.

• USPSTF GLP-1 pathway: USPSTF is developing draft recommendations on weight-loss interventions. If they expand the B recommendation to include pharmacotherapy, this would mandate coverage under ACA — the most significant potential offset to the access collapse. Monitor for publication of the draft. Search: "USPSTF weight loss interventions draft recommendation statement 2026 pharmacotherapy GLP-1"

• Never-skilling: prospective detection search update. The Lancet editorial (August 2025) raised the alarm; the JMIR 2026 study showed training improves AI-use skills. Search for any medical school running prospective pre-AI competency baselines before AI exposure in clinical training. This is the detection gap — absence of evidence remains the finding.

Dead Ends (don't re-run these)

• Direct study of food-insecure GLP-1 users + micronutrient deficiency: Does not exist. Confirmed absence after 4 separate search attempts. Note for KB: this is a documented research gap — structural inference (GLP-1 deficiency risk + food insecurity + SNAP cuts) is the best available evidence.
• State participation in BALANCE model: No published list as of April 2026. State notification deadline is July 31, 2026. Don't search for this again until after August 2026.
• GLP-1 penetration rate in HFpEF patients: No dataset provides this. Research-scale only (~1,876 trial patients vs. ~2.2M theoretically eligible). Not searchable with better results.

Branching Points (one finding opened multiple directions)

• GLP-1 adherence complication: 14.3% two-year adherence in commercial insurance means the problem is NOT only financial access — it's behavioral/pharmacological adherence even with coverage. Direction A: investigate what behavioral support programs improve adherence (the Danish digital + GLP-1 half-dose study from Session 20 is relevant); Direction B: investigate whether the 85.7% non-adherent population shows metabolic rebound and what the population-level effect of poor adherence means for healthcare cost projections. Direction A is more actionable — what works.

• USPSTF A/B rating pathway: Direction A — monitor for the draft recommendation (future session, check after August 2026); Direction B — investigate whether anyone has filed a formal USPSTF petition specifically for GLP-1 pharmacotherapy inclusion. Direction A is passive (monitoring); Direction B is active research. Pursue Direction B if session capacity allows.

• GLP-1 access equity framing: Two frames are emerging: (1) "structural fiscal problem that ideology can't overcome" (California datum); (2) "access inversion — highest burden populations have least access" (Medicaid coverage optional precisely for highest-prevalence population). These are complementary claims for the same phenomenon. Both should be extracted, framing A for the cost-sustainability argument, framing B for the structural inequity argument.